Mark Levis, MD, PhD, explains the impact of measurable residual disease in the clinical outcomes of patients with relapsed or refractory acute myeloid leukemia (AML) at Annual Meeting 2018
Measurable residual disease in relapsed/refractory AML
Mark Levis, MD, PhD, explains the impact of measurable residual disease in the clinical outcomes of patients with relapsed or refractory acute myeloid leukemia (AML) at Annual Meeting 2018